Ophthalmology – Ocular Adnexal Lymphoma (OAL)

Basics

Description

Ocular adnexal lymphoma (OAL) is a lymphoid malignancy involving structures surrounding the globe, including the:

• Conjunctiva
• Eyelids
• Orbit
• Lacrimal gland
• Lacrimal drainage apparatus

Most OALs are:

• B-cell lymphomas
• Non-Hodgkin lymphomas

Ocular adnexal lymphoid proliferations range from:

• Reactive lymphoid hyperplasia
• Clonal lymphoproliferative disease
• Overt lymphoma

These entities cannot reliably be distinguished clinically and usually require tissue biopsy.

Important Distinction

Ocular adnexal lymphoma is different from:

Primary vitreoretinal lymphoma

Primary vitreoretinal lymphoma is usually considered part of the primary central nervous system lymphoma spectrum and involves the:

• Retina
• Vitreous
• Optic nerve in some cases

OAL, by contrast, primarily involves the ocular adnexa.

Major Histologic Subtypes

The most common ocular adnexal lymphomas include:

Indolent Lymphomas

• Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
• Follicular lymphoma
• Small lymphocytic lymphoma/chronic lymphocytic leukemia

More Aggressive Lymphomas

• Diffuse large B-cell lymphoma (DLBCL)
• Mantle cell lymphoma

The most common subtype is:

Extranodal marginal zone/MALT lymphoma

which accounts for approximately half or more of many OAL series.

Epidemiology

OAL predominantly affects:

• Middle-aged and older adults

The typical age at presentation is approximately:

60–70 years

It is uncommon in children.

There is no strong consistent sex predilection overall, although epidemiology varies among lymphoma subtypes.

OAL represents an important proportion of adult orbital malignancies.

Risk Factors

Potential risk factors include:

• Chronic immune stimulation
• Autoimmune disease
• Immunosuppression
• HIV infection
• Previous organ transplantation
• Long-term immunosuppressive therapy

Autoimmune diseases associated with increased lymphoma risk include:

• Sjögren syndrome
• Rheumatoid arthritis
• Other chronic autoimmune disorders

Genetics

There is no single inherited genetic predisposition responsible for most OAL.

Individual lymphoma subtypes may have characteristic molecular abnormalities.

Examples include alterations involving pathways of:

• NF-κB signaling
• B-cell proliferation
• Apoptosis

Molecular and cytogenetic testing may help classify difficult cases.

Pathophysiology

OAL results from clonal proliferation of lymphocytes, usually mature B cells.

The biological behavior depends heavily on the cell of origin.

For example:

• MALT lymphoma usually behaves indolently
• DLBCL is aggressive
• Mantle cell lymphoma has a strong tendency toward systemic dissemination

Chronic Immune Stimulation

Long-standing immune stimulation may contribute to development of some lymphomas.

This concept is well established in disorders such as:

• Helicobacter pylori-associated gastric MALT lymphoma

A possible association between ocular adnexal MALT lymphoma and Chlamydia psittaci has been reported in some geographic regions, but results have been inconsistent.

Therefore:

Routine antibiotic therapy is not considered standard treatment for all OAL.

Commonly Associated Conditions

Most patients have no obvious predisposing disease.

Possible associations include:

• HIV infection
• Sjögren syndrome
• Rheumatoid arthritis
• Chronic immunosuppression
• Other systemic lymphomas

Clinical Presentation

OAL typically presents with:

• Slowly progressive
• Painless
• Nonspecific

ocular or orbital symptoms.

Common complaints include:

• Eyelid swelling
• Conjunctival mass
• Proptosis
• Ptosis
• Orbital fullness
• Lacrimal gland enlargement

Diplopia and visual loss are less common.

Pain

Most indolent OAL is painless.

Pain may raise concern for:

• Aggressive lymphoma
• Rapid tumor growth
• Inflammation
• Bone involvement
• Alternative diagnosis

Conjunctival Lymphoma

The classic conjunctival appearance is a:

“Salmon-patch” lesion

This is usually:

• Pink
• Fleshy
• Smooth
• Subconjunctival
• Flat or mildly elevated

Common locations include:

• Fornix
• Bulbar conjunctiva
• Tarsal conjunctiva

Eyelid and Orbital Disease

Possible findings include:

• Painless eyelid thickening
• Palpable nodules
• Ptosis
• Proptosis
• Globe displacement
• Lacrimal gland enlargement

The lesion often molds around normal orbital structures rather than destroying them.

Lacrimal Gland Disease

Lacrimal gland lymphoma may present with:

• Superotemporal orbital fullness
• Ptosis
• Inferomedial globe displacement
• Painless gland enlargement

Lacrimal gland involvement may be associated with a greater likelihood of systemic disease than isolated conjunctival involvement.

Examination

A complete ocular examination should include:

• Visual acuity
• Pupillary responses
• Color vision when indicated
• Motility
• Globe position
• Slit-lamp examination
• Eyelid eversion
• Palpation of orbit and lacrimal gland
• Dilated fundus examination

Eyelid Eversion

Always evert the eyelids and inspect:

• Superior fornix
• Inferior fornix
• Tarsal conjunctiva

Subtle conjunctival lymphoma may otherwise be missed.

Vision and Pupils

Visual acuity and pupillary responses are often normal.

An optic neuropathy is unusual in indolent disease.

Features concerning for more advanced or aggressive disease include:

• Reduced vision
• Dyschromatopsia
• RAPD
• Optic disc edema
• Compressive optic neuropathy

Proptosis and Motility

OAL may cause:

• Mild proptosis
• Globe displacement

However, severe ophthalmoplegia or painful restrictive motility is less typical of indolent lymphoma and should raise consideration of:

• Aggressive lymphoma
• Idiopathic orbital inflammation
• Invasive infection
• Metastatic disease

Diagnosis

Definitive diagnosis requires:

Tissue biopsy

Clinical appearance alone cannot reliably distinguish:

• Reactive lymphoid hyperplasia
• MALT lymphoma
• Follicular lymphoma
• Other lymphoma subtypes

Biopsy

The goal of surgery is generally:

Adequate diagnostic tissue acquisition

rather than complete tumor excision.

Complete excision may be unnecessary and can increase morbidity.

Proper Tissue Handling

This is critical.

The specimen may need to be divided for:

• Histopathology
• Immunohistochemistry
• Flow cytometry
• Molecular studies
• Cytogenetic testing

Fresh, unfixed tissue is required for:

Flow cytometry

Therefore, coordination with pathology before biopsy is highly advisable.

Histopathology

Evaluation may establish:

• Cell lineage
• Monoclonality
• Lymphoma subtype
• Grade
• Proliferative activity

Markers vary according to subtype.

For B-cell lymphomas, immunophenotyping often includes markers such as:

• CD20
• CD79a
• PAX5

Additional markers help distinguish:

• MALT lymphoma
• Follicular lymphoma
• Mantle cell lymphoma
• DLBCL
• CLL/SLL

Reactive Lymphoid Hyperplasia

Reactive lymphoid hyperplasia is generally a:

• Polyclonal
• Benign or reactive lymphoid proliferation

However, clinically it may resemble lymphoma.

Long-term observation may be appropriate because persistent or recurrent lymphoid lesions occasionally precede or coexist with lymphoma.

Imaging

Orbital CT or MRI

Imaging is usually obtained for suspected OAL.

It helps determine:

• Extent of orbital involvement
• Lacrimal gland involvement
• Extraocular muscle involvement
• Bone changes
• Sinus extension
• Bilaterality

Typical Imaging Appearance

OAL often appears as:

• Homogeneous soft-tissue mass
• Well-defined lesion
• Infiltrative lesion molding around orbital structures

Characteristic behavior includes:

Molding to orbital anatomy without marked bone destruction

Bone Erosion

Bone erosion is uncommon in typical indolent OAL.

Its presence should raise concern for:

• Aggressive lymphoma
• Metastatic tumor
• Lacrimal gland epithelial malignancy
• Invasive infection

Conjunctival Disease and Orbital Imaging

Even apparently localized conjunctival lymphoma may have deeper orbital extension.

Therefore, orbital imaging should be considered as part of initial assessment.

Systemic Staging

After histologic confirmation, systemic staging is essential.

Evaluation commonly includes:

• Hematology/oncology consultation
• CBC with differential
• Renal function
• Liver function
• LDH
• Additional lymphoma-specific laboratory studies

PET/CT

FDG PET/CT is frequently used for staging many lymphoma subtypes.

It can identify:

• Nodal disease
• Extranodal disease
• Distant systemic involvement
• Treatment response

Its sensitivity varies according to lymphoma histology.

Bone Marrow Biopsy

Bone marrow examination may be considered depending on:

• Lymphoma subtype
• Stage
• PET/CT findings
• Blood counts
• Oncologist preference

It is no longer automatically required for every patient with every lymphoma subtype.

CNS Evaluation

Lumbar puncture or CNS evaluation is reserved for selected high-risk situations.

It is not routine for typical localized indolent OAL.

Differential Diagnosis

Important differential diagnoses include:

• Reactive lymphoid hyperplasia
• Idiopathic orbital inflammatory disease
• Sarcoidosis
• Granulomatosis with polyangiitis
• Metastatic carcinoma
• Lacrimal gland pleomorphic adenoma
• Adenoid cystic carcinoma
• Conjunctival neoplasia
• Orbital metastasis
• IgG4-related disease
• Sino-orbital fungal infection

IgG4-Related Disease

IgG4-related ophthalmic disease can closely mimic lymphoma.

It may involve:

• Lacrimal glands
• Extraocular muscles
• Infraorbital nerves
• Orbit

Histopathologic evaluation is essential because IgG4-related disease and lymphoma may occasionally coexist.

Treatment Principles

Treatment depends on:

• Histologic subtype
• Grade
• Stage
• Location
• Laterality
• Patient age
• Comorbidities

There is no single treatment appropriate for all OAL.

Localized Indolent OAL

For localized MALT or low-grade lymphoma, treatment commonly includes:

External-beam radiation therapy

This provides excellent local control.

Radiation Therapy

Conventional definitive radiation doses for localized indolent OAL are often approximately:

20–30 Gy

depending on:

• Histology
• Treatment protocol
• Anatomic site

Lower-dose regimens may be considered in selected cases.

Ultra-Low-Dose Radiation

Very low-dose radiation, such as:

4 Gy in 2 fractions

has been used for selected indolent ocular adnexal lymphomas.

Advantages include:

• Reduced treatment burden
• Lower radiation toxicity

However, local control may be less durable than with conventional definitive dosing in some patients.

An adaptive approach may be used in selected centers.

Radiation Complications

Potential ocular complications include:

• Dry eye
• Keratitis
• Cataract
• Retinopathy
• Optic neuropathy
• Lacrimal gland dysfunction

Risk depends on:

• Total dose
• Radiation field
• Ocular shielding
• Location of tumor

Rituximab

Rituximab targets CD20-positive B cells.

It may be used:

• Systemically
• As part of combination chemotherapy
• In selected recurrent or disseminated indolent B-cell lymphomas

Responses can be excellent, although recurrence may occur.

Systemic Chemotherapy

Systemic therapy is generally indicated for:

• Disseminated lymphoma
• Aggressive histologic subtype
• Certain bilateral or multifocal presentations
• Relapsed disease

Treatment is dictated by lymphoma subtype.

Diffuse Large B-Cell Lymphoma

DLBCL requires systemic oncologic treatment.

A common approach includes:

Rituximab-based multiagent chemotherapy, often an R-CHOP-type regimen when appropriate.

Radiation may also be added in selected cases.

Mantle Cell Lymphoma

Mantle cell lymphoma is commonly associated with:

• Bilateral ocular involvement
• Systemic disease
• More aggressive clinical behavior

It usually requires systemic hematologic treatment rather than local therapy alone.

Follicular Lymphoma

Management depends on:

• Stage
• Grade
• Symptoms

Localized disease may be treated with radiation.

Systemic disease may require:

• Observation in selected low-burden cases
• Rituximab
• Systemic immunochemotherapy

Observation

Observation may be appropriate in selected patients with:

• Completely excised very small indolent lesions
• Significant comorbidity
• Very low disease burden
• No systemic involvement

However, careful systemic staging and long-term surveillance remain necessary.

Antibiotic Therapy

Antibiotics have been investigated because of the proposed association between some MALT lymphomas and infectious organisms.

However:

Routine empiric antibiotic treatment is not standard for OAL.

Any such treatment should be based on:

• Geographic evidence
• Demonstrated infection
• Specialist recommendations

Role of Surgery

Surgery is mainly used for:

Diagnosis

rather than definitive tumor removal.

Extensive orbital excision is generally avoided because:

• Lymphoma is radiosensitive
• Lymphoma is chemosensitive
• Complete excision may cause unnecessary morbidity

Referral

All confirmed OAL should generally be managed with:

• Ophthalmology/oculoplastic surgery
• Hematology-oncology

Additional involvement may include:

• Radiation oncology
• Pathology
• Medical oncology

Prognostic Factors

Prognosis depends predominantly on:

• Histologic subtype
• Systemic stage
• Response to treatment

Generally favorable features include:

• Localized disease
• Unilateral conjunctival involvement
• MALT histology

Less favorable features include:

• Aggressive histology
• Bilateral disease
• Eyelid involvement
• Lacrimal gland involvement
• Bone destruction
• Optic neuropathy
• Systemic dissemination

Follow-Up

Long-term surveillance is essential because OAL may:

• Recur locally
• Appear in the fellow orbit
• Develop at distant extranodal sites
• Become associated with systemic lymphoma

Follow-up often continues for:

Years to decades

Ocular Monitoring

Initially, patients may be examined every few weeks or months during therapy.

Later surveillance evaluates:

• Conjunctiva
• Eyelids
• Orbit
• Lacrimal gland
• Motility
• Vision
• Treatment complications

Once stable, follow-up intervals may extend to:

6–12 months

depending on subtype and oncologic guidance.

Systemic Monitoring

Systemic surveillance is coordinated by oncology and may include:

• Clinical examination
• Blood tests
• PET/CT or other imaging when indicated

The exact schedule depends on lymphoma subtype and stage.

Patient Education

Patients should understand that:

• OAL is not a single disease.
• Prognosis depends strongly on histologic subtype.
• Even localized disease requires systemic staging.
• Long-term follow-up remains necessary after successful treatment.
• Recurrence may occur years after initial therapy.

Prognosis

MALT / Extranodal Marginal Zone Lymphoma

Usually:

• Indolent
• Highly treatment-responsive
• Associated with excellent disease-specific survival

Local recurrence or systemic dissemination can nevertheless occur.

Follicular Lymphoma

Usually has an indolent course but may:

• Recur
• Become systemic
• Rarely transform to a more aggressive lymphoma

DLBCL

DLBCL is an aggressive malignancy requiring prompt systemic therapy.

Prognosis depends on:

• Stage
• Age
• Performance status
• Molecular characteristics
• Treatment response

Mantle Cell Lymphoma

Mantle cell lymphoma often has:

• Greater systemic involvement
• Higher recurrence risk
• More aggressive behavior

than MALT lymphoma.

Modern targeted therapies have substantially changed management compared with older historical series.

Complications

Local Disease Complications

Possible complications include:

• Recurrence
• Proptosis
• Diplopia
• Ptosis
• Optic nerve compression
• Visual loss

Treatment-Related Complications

Radiation may cause:

• Dry eye
• Cataract
• Keratitis
• Retinopathy
• Optic neuropathy

Systemic therapy may cause:

• Cytopenias
• Infection
• Organ toxicity
• Other regimen-specific complications

Disease-Related Complications

Potential long-term complications include:

• Systemic dissemination
• Relapse
• Transformation to a more aggressive lymphoma
• Treatment failure

Ophthalmology Pearls

• Ocular adnexal lymphoma involves the conjunctiva, eyelids, orbit, lacrimal gland, or lacrimal drainage system.
• The most common subtype is extranodal marginal zone/MALT lymphoma.
• The classic conjunctival lesion is a painless salmon-patch mass.
• Always evert the eyelids to inspect the fornices and tarsal conjunctiva.
• OAL usually presents as a slow-growing, painless lesion; pain, bone destruction, or optic neuropathy should raise concern for more aggressive disease.
• OAL often molds around orbital structures rather than destroying them.
• Clinical examination cannot reliably distinguish reactive lymphoid hyperplasia from lymphoma—biopsy is required.
• Correct specimen handling is critical: fresh tissue is needed for flow cytometry, while formalin-fixed tissue is used for routine histology and immunohistochemistry.
• Surgery is primarily diagnostic, not an attempt at wide complete excision.
• Every confirmed OAL requires systemic staging and hematology-oncology involvement.
• Localized indolent OAL is highly responsive to radiation therapy.
• Aggressive subtypes such as DLBCL and mantle cell lymphoma generally require systemic therapy.
• OAL is distinct from primary vitreoretinal lymphoma, which belongs to the CNS lymphoma spectrum.
• Even after successful local treatment, long-term systemic and ophthalmic surveillance is mandatory.